Ucb SA

Chart & Performance

D1W1MN

P/E

103.21

P/S

6.74

EPS

1.81

Div Yield, %

0.71%

Shrs. gr., 5y

0.70%

Rev. gr., 5y

2.54%

Revenues

5.25b

-4.80%

Net income

343m

-17.94%

CFO

761m

-27.18%

Dividend

Apr 26, 20241.36 EUR/sh

Earnings

Feb 27, 2025

Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

URL

https://www.ucb.com

IPO date

Jan 02, 1987

Employees

8,600

Domiciled in

Incorporated in

Valuation

Order:

Title EUR in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title EUR in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	5,252,000 -4.80%	5,517,000 -4.50%	5,777,000 8.04%
Cost of revenue	5,161,000	5,247,000	4,795,000
Unusual Expense (Income)
NOPBT	91,000	270,000	982,000
NOPBT Margin	1.73%	4.89%	17.00%
Operating Taxes	98,000	91,000	170,000
Tax Rate	107.69%	33.70%	17.31%
NOPAT	(7,000)	179,000	812,000
Net income	343,000 -17.94%	418,000 -60.49%	1,058,000 44.54%
Dividends	(252,000)	(247,000)	(240,000)
Dividend yield	1.64%	1.72%	1.23%
Proceeds from repurchase of equity	(40,000)	(405,000)	779,000
BB yield	0.26%	2.83%	-4.00%
Debt
Debt current	85,000	262,000	55,000
Long-term debt	3,157,000	2,638,000	2,068,000
Deferred revenue		100,000	97,000
Other long-term liabilities	666,000	677,000	741,000
Net debt	2,150,000	1,653,000	565,000
Cash flow
Cash from operating activities	761,000	1,045,000	1,490,000
CAPEX	(238,000)	(371,000)	(493,000)
Cash from investing activities	(440,000)	(1,580,000)	(487,000)
Cash from financing activities	(308,000)	144,000	(1,056,000)
FCF	(225,000)	20,000	572,000
Balance
Cash	923,000	1,069,000	1,373,000
Long term investments	169,000	178,000	185,000
Excess cash	829,400	971,150	1,269,150
Stockholders' equity	7,298,000	7,397,000	6,751,000
Invested Capital	11,892,600	11,619,850	9,949,850
ROIC		1.66%	8.37%
ROCE	0.70%	2.08%	8.61%
EV
Common stock shares outstanding	195,190	194,834	194,177
Price	78.90 7.26%	73.56 -26.70%	100.35 18.79%
Market cap	15,400,491 7.46%	14,331,989 -26.45%	19,485,662 18.74%
EV	17,550,491	15,984,989	20,050,662
EBITDA	782,000	855,000	1,305,000
EV/EBITDA	22.44	18.70	15.36
Interest	144,000	71,000	45,000
Interest/NOPBT	158.24%	26.30%	4.58%